Inhibitors of prenylation of Ras and other G-proteins and their application as therapeutics

Biochemical Pharmacology

Volumn 60, Issue 8, 2000, Pages 1061-1068

  Cohen, Louis H ^a   Pieterman, Elsbet ^a   Van Leeuwen, Rick E W ^a   Overhand, Mark ^a   Burm, Brigitte E A ^a   Van Der Marel, Gijs A ^a   Van Boom, Jacques H ^a  

^a LEIDEN UNIVERSITY   (Netherlands)

Author keywords

Angiogenesis; Cancer; Human smooth muscle cells; Osteoporosis; Protein:farnesyl transferase; Protein:geranylgeranyl transferase; Restenosis

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; FARNESYL DIPHOSPHATE; GERANYLTRANSFERASE; GUANINE NUCLEOTIDE BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN FARNESYLTRANSFERASE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; RAS PROTEIN; STATIN; TR 006; UNCLASSIFIED DRUG;

ANGIOGENESIS; ATHEROSCLEROSIS; CANCER; CELL DIFFERENTIATION; CELL GROWTH; CORONARY ARTERY OBSTRUCTION; DRUG DESIGN; DRUG MECHANISM; HUMAN; HUMAN CELL; OSTEOPOROSIS; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRENYLATION; PRIORITY JOURNAL; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION;

EID: 0034668174     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(00)00386-5     Document Type: Article

References (58)

1. Maltese W.A. Posttranslational modification of proteins by isoprenoids in mammalian cells. FASEB J. 4:1990;3319-3328.
2. Clarke S. Protein isoprenylation and methylation at carboxyl-terminal cysteine residues. Annu Rev Biochem. 61:1992;355-386.
3. Casey P.J. Biochemistry of protein prenylation. J Lipid Res. 33:1992;1731-1740.
4. Fu H.W., Casey P.J. Enzymology and biology of CaaX protein prenylation. Recent Prog Horm Res. 54:1999;315-342.
5. Maltese W.A., Sheridan K.M. Isoprenylated proteins in cultured cells Subcellular distribution and changes related to altered morphology and growth arrest induced by mevalonate deprivation . J Cell Physiol. 133:1987;471-481.
6. Luckman S.P., Hughes D.E., Coxon F.P., Graham R., Russell G., Rogers M.J. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res. 13:1998;581-589.
7. van Beek E., Lowik C., van der Pluijm G., Papapoulos S. The role of geranylgeranylation in bone resorption and its suppression by bisphosphonates in fetal bone explants in vitro A clue to the mechanism of action of nitrogen-containing bisphosphonates . J Bone Miner Res. 14:1999;722-729.
8. van Beek E., Pieterman E., Cohen L., Lowik C., Papapoulos S. Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates. Biochem Biophys Res Commun. 264:1999;108-111.
9. Keller R.K., Fliesler S.J. Mechanism of aminobisphosphonate action Characterization of alendronate inhibition of the isoprenoid pathway . Biochem Biophys Res Commun. 266:1999;560-563.
10. Bergstrom J.D., Bostedor R.G., Masarachia P.J., Reszka A.A., Rodan G. Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase. Arch Biochem Biophys. 373:2000;231-241.
11. Gibbs J.B., Oliff A., Kohl N.E. Farnesyltransferase Inhibitors Ras research yields a potential cancer therapeutic . Cell. 77:1994;175-178.
12. Leonard D.M. Ras farnesyltransferase A new therapeutic target . J Med Chem. 40:1997;2971-2990.
13. Sebti S.M., Hamilton A.D. Inhibition of Ras prenylation A novel approach to cancer chemotherapy . Pharmacol Ther. 74:1997;103-114.
14. Cox A.D., Der C.J. Farnesyltransferase inhibitors and cancer treatment Targeting simply Ras? Biochim Biophys Acta. 1333:1997;F51-F71.
15. Libby P., Schwartz D., Brogi E., Tanaka H., Clinton S.K. A cascade model for restenosis. A special case of atherosclerosis progression. Circulation. 86:1992;III47-III52.
16. Indolfi C., Avvedimento E.V., Rapacciuolo A., Di Lorenzo E., Esposito G., Stabile E., Feliciello A., Mele E., Giuliano P., Condorelli G. Inhibition of cellular ras prevents smooth muscle cell proliferation after vascular injury in vivo. Nat Med. 1:1995;541-545.
17. Valentijn A.R., van den Berg O., van der Marel G.A., Cohen L.H., van Boom J.H. Synthesis of pyrophosphonic acid analogues of farnesyl pyrophosphate. Tetrahedron. 51:1995;2099-2108.
18. Overhand M., Pieterman E., Cohen L.H., Valentijn A.R., van der Marel G.A., van Boom J.H. Synthesis of triphosphonate analogues of farnesyl pyrophosphate. Inhibitors of squalene synthase and protein:farnesyl transferase. Bioorg Med Chem Lett. 7:1997;2435-2440.
19. Overhand M., Stuivenberg H.R., Pieterman E., Cohen L.H., van Leeuwen R.E., Valentijn A.R., Overkleeft H.S., van der Marel G.A., van Boom J.H. Inhibitors of protein:farnesyl transferase and protein:geranylgeranyl transferase I Synthesis of homologous diphosphonate analogs of isoprenylated pyrophosphate . Bioorg Chem. 26:1998;269-282.
20. Overkleeft H.S., Verhelst S.H., Pieterman E., Meeuwenoord N.J., Overhand M., Cohen L.H., van der Marel G.A., van Boom J.H. Design and synthesis of a protein:farnesyltransferase inhibitor based on sugar amino acids. Tetrahedron Lett. 40:1999;4103-4106.
21. Lerner E.C., Qian Y.M., Hamilton A.D., Sebti S.M. Disruption of oncogenic k-ras4b processing and signaling by a potent geranylgeranyltransferase I inhibitor. J Biol Chem. 270:1995;26770-26773.
22. Vasudevan A., Qian Y., Vogt A., Blaskovich M.A., Ohkanda J., Sebti S.M., Hamilton A.D. Potent, highly selective, and non-thiol inhibitors of protein geranylgeranyltransferase-I. J Med Chem. 42:1999;1333-1340.
23. Bhide R.S., Patel D.V., Patel M.M., Robinson S.P., Hunihan L.W., Gordon E.M. Rational design of potent carboxylic acid based bisubstrate inhibitors of ras farnesyl protein transferase. Bioorg Med Chem Lett. 4:1994;2107-2112.
24. Manne V., Yan N., Carboni J.M., Tuomari A.V., Ricca C.S., Brown J.G., Andahazy M.L., Schmidt R.J., Patel D., Zahler R., Weinmann R., Der C.J., Cox A.D., Hunt J.T., Gordon E.M., Barbacid M., Seizinger B.R. Bisubstrate inhibitors of farnesyltransferase A novel class of specific inhibitors of ras transformed cells . Oncogene. 10:1995;1763-1779.
25. Freeman S., Ross K.C. Prodrug design for phosphates and phosphonates. Ellis G.P., Luscombe D.K. Progress in Medicinal Chemistry. 1997;112-147 Elsevier Science, Amsterdam.
26. Dickson J.K., Biller S.A., Magnin D.R., Petrillo E.W., Hillyer J.W., Hsieh D.C., Lan S.J., Rinehart J.K., Gregg R.E., Harrity T.W., Jolibois K.G., Kalinowski S.S., Kunselman L.K., Mookhtiar K.A., Ciosek C.P. Orally active squalene synthase inhibitors Bis((acyloxy)alkyl) prodrugs of the alpha-phosphonosulfonic acid moiety . J Med Chem. 39:1996;661-664.
27. Negre-Aminou P., Van Vliet A.K., van Erck M., van Thiel G.C., van Leeuwen R.E., Cohen L.H. Inhibition of proliferation of human smooth muscle cells by various HMG-CoA reductase inhibitors Comparison with other human cell types . Biochim Biophys Acta. 1345:1997;259-268.
28. Cohen L.H., Valentijn A.R., Roodenburg L., van Leeuwen R.E., Huisman R.H., Lutz R.J., van der Marel G.A., van Boom J.H. Different analogues of farnesyl pyrophosphate inhibit squalene synthase and protein:farnesyltransferase to different extents. Biochem Pharmacol. 49:1995;839-845.
29. Cohen L.H., Pieterman E., van Leeuwen R.E., Du J., Negre-Aminou P., Valentijn A.R., Overhand M., van der Marel G.A., van Boom J.H. Inhibition of human smooth muscle cell proliferation in culture by farnesyl pyrophosphate analogues, inhibitors of in vitro protein:farnesyl transferase. Biochem Pharmacol. 57:1999;365-373.
30. Terano T., Shiina T., Noguchi Y., Tanaka T., Tatsuno I., Saito Y., Yasuda T., Kitagawa M., Hirai A. Geranylgeranylpyrophosphate plays a key role for the G1 to S transition in vascular smooth muscle cells. J Atheroscler Thromb. 5:1998;1-6.
31. Laufs U., Marra D., Node K., Liao J.K. 3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors attenuate vascular smooth muscle proliferation by preventing rho GTPase-induced down-regulation of p27(Kip1). J Biol Chem. 274:1999;21926-21931.
32. Stark W.W., Blaskovich M.A., Johnson B.A., Qian Y., Vasudevan A., Pitt B., Hamilton A.D., Sebti S.M., Davies P. Inhibiting geranylgeranylation blocks growth and promotes apoptosis in pulmonary vascular smooth muscle cells. Am J Physiol. 275:1998;L55-L63.
33. Guijarro C., Blanco-Colio L.M., Ortego M., Alonso C., Ortiz A., Plaza J.J., Diaz C., Hernandez G., Edigo J. 3-Hydroxy-3-methylglutaryl coenzyme a reductase and isoprenylation inhibitors induce apoptosis of vascular smooth muscle cells in culture. Circ Res. 83:1998;490-500.
34. Olson M.F., Ashworth A., Hall A. An essential role for Rho, Rac, and Cdc42 GTPases in cell cycle progression through G1. Science. 269:1995;1270-1272.
35. Bos J.L. Ras oncogenes in human cancer A review . Cancer Res. 49:1989;4682-4689.
36. Jackson J.H., Cochrane C.G., Bourne J.R., Solski P.A., Buss J.E., Der C.J. Farnesol modification of Kirsten-ras exon 4B protein is essential for transformation. Proc Natl Acad Sci USA. 87:1990;3042-3046.
37. Kato K., Cox A.D., Hisaka M.M., Graham S.M., Buss J.E., Der C.J. Isoprenoid addition to ras protein is the critical modification for its membrane association and transforming activity. Proc Natl Acad Sci USA. 89:1992;6403-6407.
38. Gibbs J.B. Ras C-terminal processing enzymes - new drug targets? Cell. 65:1991;1-4.
39. Khosravifar R., Cox A.D., Kato K., Der C.J. Protein prenylation Key to ras function and cancer intervention? Cell Growth Differ. 3:1992;461-469.
40. Kohl N.E., Mosser S.D., deSolms S.J., Giuliani E.A., Pompliano D.L., Graham S.L., Smith R.L., Scolnick E.M., Oliff A., Gibbs J.B. Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor. Science. 260:1993;1934-1936.
41. Zujewski J., Horak I.D., Bol C.J., Woestenborghs R., Bowden C., End D.W., Piotrovsky V.K., Chiao J., Belly R.T., Todd A., Kopp W.C., Kohler D.R., Chow C., Noone M., Hakim F.T., Larkin G., Gress R.E., Nussenblatt R.B., Kremer A.B., Cowan K.H. Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer. J Clin Oncol. 18:2000;927.
42. Kohl N.E., Omer C.A., Conner M.W., Anthony N.J., Davide J.P., deSolms S.J., Giuliani E.A., Gomez R.P., Graham S.L., Hamilton K., Handt L.K., Hartman G.D., Koblan K.S., Kral A.M., Miller P.J., Mosser S.D., O'Neill T.J., Rands E., Schaber M.D., Gibbs J.B., Oliff A. Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice. Nat Med. 1:1995;792-797.
43. Liu M., Bryant M.S., Chen J., Lee S., Yaremko B., Lipari P., Malkowski M., Ferrari E., Nielsen L., Prioli N., Dell J., Sinha D., Syed J., Korfmacher W.A., Nomeir A.A., Lin C.C., Wang L., Taveras A.G., Doll R.J., Njoroge F.G., Mallams A.K., Remiszewski S., Catino J.J., Girijavallabhan V.M., Bishop W.R. Antitumor activity of SCH 66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and wap-ras transgenic mice. Cancer Res. 58:1998;4947-4956.
44. Rowinsky E.K., Windle J.J., Von Hoff D.D. Ras protein farnesyltransferase A strategic target for anticancer therapeutic development . J Clin Oncol. 17:1999;3631-3652.
45. Mazet J.L., Padieu M., Osman H., Maume G., Mailliet P., Dereu N., Hamilton A.D., Lavelle F., Sebti S.M., Maume B.F. Combination of the novel farnesyltransferase inhibitor RPR130401 and the geranylgeranyltransferase-1 inhibitor GGTI-298 disrupts MAP kinase activation and G(1)-S transition in Ki-Ras-overexpressing transformed adrenocortical cells. FEBS Lett. 460:1999;235-240.
46. Lebowitz P.F., Prendergast G.C. Non-Ras targets of farnesyltransferase inhibitors Focus on Rho . Oncogene. 17:1998;1439-1445.
47. Du W., Lebowitz P.F., Prendergast G.C. Cell growth inhibition by farnesyltransferase inhibitors is mediated by gain of geranylgeranylated RhoB. Mol Cell Biol. 19:1999;1831-1840.
48. Folkman J. The influence of angiogenesis research on management of patients with breast cancer. Breast Cancer Res Treat. 36:1995;109-118.
49. Gu W.Z., Tahir S.K., Wang Y.C., Zhang H.C., Cherian S.P., O'Connor S., Leal J.A., Rosenberg S.H., Ng S.C. Effect of novel CAAX peptidomimetic farnesyltransferase inhibitor on angiogenesis in vitro and in vivo. Eur J Cancer. 35:1999;1394-1401.
50. Feldkamp M.M., Lau N., Guha A. Growth inhibition of astrocytoma cells by farnesyl transferase inhibitors is mediated by a combination of anti-proliferative, pro-apoptotic and anti-angiogenic effects. Oncogene. 18:1999;7514-7526.
51. Koolwijk P., van Erck M.G., de Vree W.J., Vermeer M.A., Weich H.A., Hanemaaijer R., van Hinsbergh V.W. Cooperative effect of TNFalpha, bFGF, and VEGF on the formation of tubular structures of human microvascular endothelial cells in a fibrin matrix. Role of urokinase activity. J Cell Biol. 132:1996;1177-1188.
52. van Beek E., Pieterman E., Cohen L., Lowik C., Papapoulos S. Nitrogen-containing bisphosphonates inhibit isopentenyl pyrophosphate isomerase/farnesyl pyrophosphate synthase activity with relative potencies corresponding to their antiresorptive potencies in vitro and in vivo. Biochem Biophys Res Commun. 255:1999;491-494.
53. Fisher J.E., Rogers M.J., Halasy J.M., Luckman S.P., Hughes D.E., Masarachia P.J., Wesolowski G., Russell R.G., Rodan G.A., Reszka A.A. Alendronate mechanism of action Geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro . Proc Natl Acad Sci USA. 96:1999;133-138.
54. Clohisy D.R., Ramnaraine M.L. Osteoclasts are required for bone tumors to grow and destroy bone. J Orthop Res. 16:1998;660-666.
55. Mundy G., Garrett R., Harris S., Chan J., Chen D., Rossini G., Boyce B., Zhao M., Gutierrez G. Stimulation of bone formation in vitro and in rodents by statins. Science. 286:1999;1946-1949.
56. Rogers M.J. Statins Lower lipids and better bones? Nat Med. 6:2000;21-23.
57. Khwaja A., O'Connolly J., Hendry B.M. Prenylation inhibitors in renal disease. Lancet. 355:2000;741-744.
58. Goldstein J.L., Brown M.S., Stradley S.J., Reiss Y., Gierasch L.M. Nonfarnesylated tetrapeptide inhibitors of protein farnesyltransferase. J Biol Chem. 266:1991;15575-15578.